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ABSTRACT 
Objective: This study was undertaken to explore the efficacy and safety of Citrus sudachi 
peel for metabolic risk factors in obese male and female adults.   
 
Background: Citrus sudachi Hort. ex Shirai (Rutaceae), called “sudachi”, is a small, round, 
green  citrus  fruit  that  is  mainly  cultivated  in  Tokushima  Prefecture  in  Japan.  Our  group 
reported that Citrus sudachi peel powder improved glucose tolerance and dyslipidemia in 
Zucher-fatty rats and reduced hyperglycemia and hypertriglyceridemia in GK diabetic rats. 
 
Materials and Methods: We conducted a randomized, double-blind, placebo-controlled trial 
in 40 participants with abdominal obesity and metabolic risk factors including hypertension, 
impaired glucose tolerance and elevated triglyceride levels. Participants were randomized to 
receive either tablets that contained 1.3 g dried Citrus sudachi peel powder or placebo tablets 
for 12 weeks. The sudachi peel group included 14 males and 5 females with a mean age of 
54.5 years, and the placebo group included 18 males and 2 females with a mean age of 51.9 
years.     
 
Results: Physical status including body weight, waist circumference and blood pressure and 
laboratory markers including metabolic parameters were not different at any observation point 
between the two groups. However, among participants with serum triglyceride levels of more Functional Foods in Health and Disease 2014; 4(6):276-284                            Page 277 of 284 
 
 
than  120  mg/dl,  body  weight,  waist  circumference  and  serum  triglyceride  levels  were 
significantly decreased at several observation points after the start of treatment in the sudachi 
peel group but not in the placebo group. No serious adverse events were observed in the 
sudachi peel group.   
 
Conclusions: Citrus sudachi peel has the potential effect to safely improve abdominal obesity 
and lower serum levels of TG in obese individuals with hypertriglyceridemia. A large-scale 
randomized, double-blind clinical study targeting subjects with both abdominal obesity and 
high TG levels is needed to confirm the metabolic effects of Citrus sudachi peel. 
 
Trial  registration:  UMIN  Clinical  Trials  Registry  (UMIN-CTR)  UMIN000002682.  
Accession  number  of  the  Ethics  Committee  for  Clinical  Trials  of  Food  in  Tokushima 
University Hospital is F5. 
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BACKGROUND: 
Citrus sudachi Hort. ex Shirai (Rutaceae), called “sudachi”, is a small, round, green citrus 
fruit that is mainly cultivated in Tokushima Prefecture in Japan [1]. Slices of this fruit are 
often used for Japanese dishes as food flavoring in place of vinegar and the peel is also edible.  
Our  group  reported  that  Citrus  sudachi  peel  powder  improved  glucose  tolerance  and 
dyslipidemia in Zucher-fatty rats and reduced hyperglycemia and hypertriglyceridemia in GK 
diabetic rats [2]. However, the effects of Citrus sudachi peel on lifestyle-related risk factors in 
humans have not been clarified. Metabolic syndrome is a combination of lifestyle-related risk 
factors that increase the risk of developing cardiovascular disease and diabetes [3]. The aim of 
this  study  was  to  explore  the  efficacy  and  safety  of  Citrus  sudachi  peel  for  improving 
lifestyle-related risk factors including obesity, hypertension, impaired glucose tolerance and 
dyslipidemia in humans. 
 
METHODS: 
Subjects: Inclusion criteria were males and females aged 20 - 74 years who had abdominal 
obesity defined as waist circumference >85cm for males or >90cm for females or body mass 
index (BMI) >25 and any one of the following: 1) fasting plasma glucose (FPG) >100 mg/dL 
(5.6 mmol/L)  or  specific  treatment  for  type  2  diabetes,  2)  serum  triglycerides  (TG)   
>150 mg/dL  (1.7 mmol/L)  or  high-density  lipoprotein  cholesterol    (HDL-C)  <40 mg/dL 
(1.03 mmol/L) or specific treatment for its abnormality, and 3) systolic blood pressure (BP)   
>130 or diastolic BP >85mmHg or treatment of hypertension. The following subjects were 
excluded:  1)  subjects  with  complications  in  the  brain,  heart,  kidney,  lungs  or  liver 
(cerebrovascular accident, myocardial infraction, angina pectoris, history of cardiovascular 
intervention,  heart  failure,  arteriosclerosis  obliterans,  nephropathy,  bronchial  asthma, 
pulmonary emphysema, pneumonitis, pulmonary fibrosis, viral hepatitis, cirrhosis, diabetic 
complications,  and  diabetes  treated  with  insulin),  2)  subjects  in  whom  additional 
pharmaceutical agents should be considered for hypertension, lipid disorder, diabetes mellitus 
and/or other diseases, 3) subjects with overt systemic diseases, 4) subjects with a history of 
malignant diseases, 5) subjects who participated in another clinical trial, and 6) subjects who Functional Foods in Health and Disease 2014; 4(6):276-284                            Page 278 of 284 
 
 
were not appropriate in the attending physicians' opinion. 
 
Experimental  design:  This  study  was  designed  as  a  randomized,  double-blind, 
placebo-controlled trial.    Participants were randomized to receive either 5 tablets that in total 
contained 1.3 g dried Citrus sud achi peel powder (sudachi peel group) or 5 placebo tablets 
(placebo  group)  every  day  for  12  weeks.  Daily  intake  in  the  sudachi  peel  group  was 
equivalent to 1/3 of a whole Citrus sudachi. Since analysis carried out by the Japan Food 
Research Laboratories showed that the content of synephrine in Citrus sudachi peel is 2.5 
mg/g, estimated intake of synephrine, which is contained in abundance in citrus peel and has 
pharmacological effects similar to those of ephedrine, was only 3.25 mg/day in the sudachi 
peel group. Analysis carried out by the Japan Food Research Laboratories also showed that 
the content of hesperidin, a flavonoid found abundantly in citrus fruits, was 7.4 mg/g in Citrus 
sudachi peel, indicating that the estimated intake of hesperidin was only 9.62 mg/day in the 
sudachi peel group. The study period was 17 weeks including a 1-week observation period 
before  treatment,  12-week  treatment  period  with  Citrus  sudachi  peel  powder  or  placebo 
tablets and 4-week observation period after treatment. The subjects made visits to the hospital 
1 week before the treatment, 4, 8 and 12 weeks after the start of treatment, and 4 weeks after 
the treatment period. A life diary including physical activity and exercise was recorded every 
day during the study period and a diet diary including content of meals was recorded for three 
days before each visit. The number of remaining tablets was checked at each point of visit to 
assess the compliance of subjects. Physical examination including measurements of height, 
body weight, BMI, waist circumference, BP and pulse was performed at each visit. Urine and 
blood samples were drawn from the antecubital vein after an overnight fast at each visit.     
 
Biochemical analysis: General laboratory tests were also carried out at each visit. The tests 
included urinalysis to assess urinary protein, occult blood, urobilinogen, sugar and ketone 
bodies,  measurements  of  peripheral  blood  including  white  blood  cells,  red  blood  cells, 
hemoglobin, hematocrit and platelets, assessment of liver function including measurements of 
GOT,  GPT,  LDH,  total  bilirubin,  alkaline  phosphatase,  γGTP,  total  protein  and  albumin, 
assessment of renal function including measurements of BUN and creatinine, measurements 
of  electrolytes  including  sodium,  potassium,  chloride,  and  calcium  concentrations,  and 
assessment  of  metabolic  function  including  measurements  of  low-density  lipoprotein 
(LDL)-C, HDL-C, TG, FPG, HbA1c (National Glycohemoglobin Standardization Program), 
immunoreactive insulin (IRI), and uric acid (UA).    In addition, blood levels of remnant-like 
particles (RLP)-C, free fatty acid (FFA), high-sensitivity C-reactive protein (hs-CRP), tumor 
necrosis  factor  (TNF)-  and  adiponectin  and  urinary  excretion  of 
8-hydroxy-2'-deoxyguanosine (8-OHdG) as  a marker of oxidative stress  were examined 1 
week before treatment, 12 weeks after the start of treatment and 4 weeks after the treatment 
period.  Hs-CRP  levels  were  measured  at  Bio  Medical  Laboratories  (Tokyo,  Japan)  by 
nephelometry,  a  latex  particle-enhanced  immunoassay  (N  Latex  CRP  II).  TNF-  was 
measured by ELISA (Human TNF- TNFSF1A, R&D Systems, Inc., Minneapolis, USA).   
Adiponectin  was  measured  by  ELISA  (Human  adiponection  ELISA  Kit,  Otsuka 
Pharmaceutical  Co.,  Ltd,  Tokyo,  Japan).  Urinary  excretion  of  8-hydroxydeoxyguanosine 
(OHdG) was determined by ELISA (new 8-OHdG Check ELISA Kit, Japan Institute for the 
Control of Aging, Nikken SEIL Corporation, Shizuoka, Japan) and expressed in g/g Functional Foods in Health and Disease 2014; 4(6):276-284                            Page 279 of 284 
 
 
creatinine after correction by urinary creatinine concentration.     
 
Ethics:  The  present  clinical  study  is  in  compliance  with  the  Helsinki  Declaration.  Prior 
written informed consent was obtained from all subjects before enrollment in this study in 
accordance with protocols approved by the Ethics Committee for Clinical Trials of Food in 
Tokushima  University  Hospital  (accession  number  F5).  This  study  was  registered  in  the 
UMIN Clinical Trials Registry (UMIN-CTR) with the trial number of UMIN000002682. 
 
Statistical Analysis: All parameters before and after treatment were compared between the 
sudachi peel group and the placebo group using generalized linear mixed model analysis.   
Differences in baseline patient characteristics between the two groups were analyzed by the 
unpaired t-test.    The Wilcoxon signed rank test was used to assess significant changes in 
parameters after the start of treatment in each group. All data are expressed as means ± S.D.   
The analyses were performed on a Microsoft Windows computer running SPSS software.  
Differences were considered statistically significant at p < 0.05. 
 
RESULTS: 
Basal characteristics: Forty subjects were enrolled in this study, but one subject could not 
visit our hospital due to personal reasons. Finally, the sudachi peel group included 14 males 
and 5 females  with  a  mean age of 54.5  years (one patient  having  dropped out),  and the 
placebo group included 18 males and 2 females with a mean age of 51.9 years.    The patients’ 
characteristics are summarized in Table 1. The first, second and third quartile of TNFα levels 
is 1.3, 3.4 and 4.7 pg/mL in the placebo group, respectively, and 2.1, 2.3 and 3.2 pg/mL in the 
Sudachi peel group, respectively. There were no differences in basal parameters including age, 
sex, BMI, waist circumference, pulse, BP, TG, HDL-C, HbA1c and FPG between the sudachi 
peel group and the placebo group. 
 
Intake rate of tablets: There was no difference between the intake rates of tablets in the two 
groups (95.36.7 % in the sudachi peel group and 96.16.0 % in the placebo group). 
 
Live  and  diet  diary:  Physical  activity  and  dietary  intake  of  total  calories  and  nutrients 
including  carbohydrates,  proteins  and  lipids  were  not  different  before,  during  and  after 
treatment in either the sudachi peel group or placebo group. There were also no differences in 
these parameters at every observation point between the two groups. 
 
Changes in parameters before, during and after treatment: Physical status including body 
weight, BMI, waist circumference, pulse and BP and laboratory markers including urinalysis, 
peripheral blood, liver function, renal function, electrolytes, LDL-C, TG, HDL-C, RLP-C, 
FFA, HbA1c, FPG, IRI, UA, hs-CRP, urinary 8-OHdG, TNF- and adiponectin were not 
different at any observation point between the two groups. There were also no differences in 
theses parameter before and 4, 8 and 12 weeks after the start of treatment and at 4 weeks after 
the treatment period in either the sudachi peel group or placebo group. 
                                                                                                                                         
Adverse effects: One patient in the placebo group developed dizziness and palpitation due to   
paroxysmal atrial fibrillation. None of the patients in the sudachi peel group showed   Functional Foods in Health and Disease 2014; 4(6):276-284                            Page 280 of 284 
 
 
expression or worsening of symptoms. 
 
Table 1. Baseline parameters in all subjects 
 
Variables 
Placebo group 
n=20 
Sudachi peel group 
n=19 
P-value 
Age  51.911.0  54.5  8.9  ns 
Male : Female  18:2  14:5  ns 
Body weight (kg)  76.2 10.8  75.610.9  ns 
BMI  26.2  3.4  26.8  3.0  ns 
    Waist circumference(cm)  93.7  6.1  97.3  6.3  Ns 
Pulse (bpm)  73.5  5.8  71.9  8.2  ns 
Systolic BP (mmHg)  128.9  13.0  134.6  10.5  ns 
Diastolic BP (mmHg)  82.3  6.2  87.9  8.3  ns 
LDL-C (mg/dL)  134.7  25.2  140.8  20.4  ns 
TG (mg/dL)  143.8  67.0  146.6  60.3  ns 
HDL-C (mg/dL)  62.9  15.1  67.7  15.8  ns 
RLP-C (mg/dL)  9.6  5.8  9.8  5.4  ns 
FFA (Eq/L)  538.5  133.1  548.6  197.2  ns 
HbA1c (%)  6.0  0.3  5.9  0.4  ns 
FPG (mg/dL)  112.2  13.3  108.7  14.1  ns 
IRI (g/dL)  8.0  3.1  7.7  3.6  ns 
UA (mg/dL)  6.2  1.4  5.8  1.0  ns 
hsCRP (g/dL)  100  116  93  98  ns 
U-8OHdG(g/gCr)    9.9  4.6  11.9  7.5  ns 
TNFα (pg/mL)  4.0  4.1  6.2  15.4  ns 
Adiponectin(g/mL)    6.1  2.3  6.5  2.4  ns 
 
Analysis in a subgroup with serum TG levels of more than 120 mg/dL: Since none of the 
parameters were changed by treatment with Citrus sudachi peel, we next analyzed the data in 
subjects with serum TG levels of more than 120 mg/dl. Although age and blood pressure of 
the sudachi peel subgroup with serum TG levels of more than 120 mg/dl were slightly higher 
than those of the placebo subgroup with serum TG levels of more than 120 mg/dl, there were 
no significant differences in other baseline parameters between the two subgroups (Table 2).  
The first, second and third quartile of TNFα levels is 3.5, 4.1 and 5.9 pg/mL in the placebo 
group, respectively, and 2.2, 2.7 and 3.2 pg/mL in the Sudachi peel group, respectively.   Functional Foods in Health and Disease 2014; 4(6):276-284                            Page 281 of 284 
 
 
Table 2. Baseline parameters in subjects with serum TG levels of more than 120 mg/dl 
 
Variables 
Placebo group 
n=11 
Sudachi peel group 
n=11 
P-value 
Age  47.311.0  56.3  8.2  0.046 
Male : Female  9:2  8:3  ns 
Body weight (kg)  79.1 12.9  76.911.9  ns 
BMI  26.8  4.0  27.5  3.4  ns 
Waist circumference (cm)  95.4  6.8  99.1  6.3  ns 
Pulse (bpm)  74.5  6.6  73.8  9.7  ns 
Systolic BP (mmHg)  126.7  9.7  135.5  8.1  0.049 
Diastolic BP (mmHg)  82.0  6.1  89.5  9.6  0.042 
LDL-C (mg/dL)  138.6  27.8  143.4  21.5  ns 
TG (mg/dL)  189.4  56.3  184.7  49.4  ns 
HDL-C (mg/dL)  58.4  14.5  64.7  11.8  ns 
RLP-C (mg/dL)  13.1  5.7  13.0  5.0  ns 
FFA (Eq/L)  524.0  141.3  609.5  233.1  ns 
HbA1c (%)  6.0  0.4  5.8  0.4  ns 
FPG (mg/dL)  110.4  13.0  104.6  4.4  ns 
IRI (g/dL)  8.7  1.8  8.6  4.4  ns 
UA (mg/dL)  6.0  1.6  5.8  1.2  ns 
hsCRP (g/dL)  100  89  125  119  ns 
U-8OHdG(g/gCr)    13.6  8.5  10.5  5.7  ns 
TNFα (pg/mL)  5.4  3.7  8.8  19.8  ns 
Adiponectin(g/mL)    5.8  2.1  6.7  2.3  ns 
 
In subjects with serum TG levels of more than 120 mg/dl, body weight significantly 
decreased from 76.9±11.9 kg before treatment to 76.1±11.1 kg (p<0.05) and 76.0±11.1 kg 
(p<0.05) at 8 and 12 weeks after the start of treatment, respectively, and the decrease in body 
weight was maintained 4 weeks after the treatment period (75.6±11.4 kg, p<0.01 vs before the 
treatment)  in  the sudachi  peel  subgroup, but  no significant  changes  in  body weight  were 
observed in the placebo subgroup (Figure 1A).     
Waist circumference also significantly decreased from 99.1±6.3 cm before treatment to 
97.5±6.8 cm (p<0.01) and 97.3±7.3 cm (p<0.05) at 8 and 12 weeks after the start of treatment, 
respectively, in the sudachi peel subgroup with serum TG levels of more than 120 mg/dL but 
not in the placebo subgroup (Figure 1B). Serum TG level also significantly decreased from 
184.7±49.4 mg/dL before treatment to 158.1±40.7 mg/dL (p<0.05) at 8 weeks after the start 
of treatment and to 141.2±37.1 mg/dL (p<0.01) at 4 weeks after the treatment period in the 
sudachi peel subgroup (Figure 1C). However, no significant changes in serum TG levels were 
observed in the placebo subgroup with serum TG levels of more than 120 mg/dL (Figure 1C).   Functional Foods in Health and Disease 2014; 4(6):276-284                            Page 282 of 284 
 
 
However, there was no difference in these parameters at any observation point between the 
two groups. 
 
Figure 1. Changes of parameters in the placebo subgroup (□) and the sudachi peel subgroup 
(■)  with  serum  triglyceride  levels  of  more  than  120  mg/dL.  Body  weight  was  significantly 
decreased  at  8  and  12  weeks  after  the  start  of  treatment  and  the  decrease  in  body  weight  was 
maintained 4 weeks after the treatment period in the sudachi peel subgroup (A). Waist circumference 
was also significantly decreased at 8 and 12 weeks after the start of treatment in the sudachi peel 
subgroup (B). Serum triglyceride (TG) levels were significantly decreased at 8 weeks after the start of 
treatment and at 4 weeks after the treatment period in the sudachi peel subgroup (C). Serum TG levels 
after the start of treatment significantly decreased compared with the baseline level in the sudachi peel 
group (p<0.05) (C). All data are expressed as ratios to baseline level before the start of treatment and 
means ± SEM. * p<0.05 and ** p<0.01 vs before treatment. 
 
DISCUSSION: 
This study is the first randomized, double-blind, placebo-controlled trial to clarify the effects 
and safety of Citrus sudachi peel in humans. We did not find any significant differences in 
clinical parameters between the placebo group and sudachi peel group in the present study.  
However, subgroup analysis using serum TG levels showed that intake of Citrus sudachi peel 
significantly decreased body weight, waist circumference and serum TG level in subjects with 
serum  TG  levels  of  more  than  120  mg/dL,  but  such  decreases  were  not  observed  in  the 
placebo  subgroup.  On  the  other  hand,  the  subgroup  analysis  did  not  show  significant 
differences in parameters at any observation point after the start of treatment between the 
placebo group and the sudachi peel group. These findings suggested that number of enrolled 
subjects in this study is too small to show a significant difference between the two groups.  
In addition, Taskinen et al. reported that serum TG level in obese subjects is increased by the 
combination  of  increased  secretion  and  severely  impaired  clearance  of  TG-rich  VLDL1 
particles and that increased secretion of TG-rich VLDL1 particles is linked to increased liver 
and  subcutaneous  abdominal  fat  [4],  indicating  that  obesity  with  high  TG  levels  has  a 
metabolic  pathology different  from  that in other types of  obese patients  with  normal  TG 
levels.    Taken together, a large-scale clinical study enrolling obese subjects with high TG 
levels should be designed to clarify the clinical effects of sudachi peel. 
There are several reports about the effects of components in citrus peel on metabolic 
syndrome.    Hesperidin, a flavanone glycoside found abundantly in the peel of citrus fruits, 
was  reported  to  improve  hypercholesterolemia,  hypertriglyceridemia  or  fatty  liver  in  rat 
models [5,6]. Morand et al. reported that in healthy, middle-aged, moderately overweight men, Functional Foods in Health and Disease 2014; 4(6):276-284                            Page 283 of 284 
 
 
orange  juice  decreases  diastolic  blood  pressure  and  postprandially  increases 
endothelium-dependent microvascular reactivity [7]. In Morand’s study, daily intake of 
hesperidin was 292 mg. However, in our study, estimated intake of hesperidin was quite 
low (only 9.62 mg/day) in the sudachi peel group. Synephrine contained in the peel of 
bitter orange citrus also has beneficial effect on obesity as a thermogenic agent like the 
action of ephedrine.    In our study, estimated intake of synephrine was only 3.25 mg/day.   
Colker et al. conducted the first study on the effects of a bitter orange extract containing 
58.5 mg p-synephrine and 528 mg caffeine daily on body fat loss and lipid levels in 20 
overweight adult subjects [8]. A review of human studies on Citrus aurantium (bitter 
orange)  extract  and  its  primary  protoalkaloid  p-synephrine  showed  that  products 
containing a low dose of synephrine, such as in our study, have no anti-obesity effect [9].   
Taken together, we speculate that the effect of Citrus sudachi peel on obesity and TG 
levels may not be due to synephrine. 
Nakagawa  et  al.  identified sudachitin  (4',5,7-trihydroxy-3',6,8-  trimethoxyflavone) 
and 3¢-demethoxysudachitin from Citrus sudachi peel as the most active compounds 
with  antimicrobial  activity  against  methicillin-resistant  Staphylococcus  aureus  and 
Helicobacter pylori [10]. Yuasa et al. also reported that sudachitin inhibited nitric oxide 
production  by  suppressing  the  expression  of  inducible  nitric  oxide  synthase  in 
lipopolysaccharide-stimulated  macrophages,  indicating  that  sudachitin  has  an 
anti-inflammatory effect [11]. However, no components having an anti-obesity effect or 
TG-lowering effect have so far been identified from the peel of Citrus sudachi. Further 
studies  are  needed  to  clarify  the  mechanisms  by  which  the  peel  of  Citrus  sudachi 
improves obesity and lowers serum TG levels. 
In our study, there were no adverse effects of the intake of 1.3 g dried Citrus sudachi 
peel every day for 12 weeks. There are concerns about side effects of citrus peel on the 
cardiovascular system since it contains a large amount of synephrine with ephedrine-like 
action.    In Guidelines for the Use of Synephrine in Natural Health Products revised by 
Health Canada in 2010, 30 mg/day is the maximum allowable dose for total synephrine.  
Peel of Citrus sudachi may be safe for consumption because it contains less synephrine 
than  that  in  other  citrus  peels.  However,  since  the  subjects  of  our  study  had  no 
cardiovascular complications, the safety for patients with cardiovascular diseases was not 
confirmed.    In  addition,  since  the  period  of  Citrus  sudachi  peel  intake  was  only  12 
weeks  in  our  study,  further  study  is  needed  to  show  the  safety  of  long-term  Citrus 
sudachi peel intake. 
 
CONCLUSIONS: 
Citrus sudachi peel has the potential effect to safely improve abdominal obesity and lower 
serum levels of TG in obese individuals with hypertriglyceridemia. A large-scale randomized, 
double-blind clinical study targeting subjects with both abdominal obesity and high TG levels 
is needed to confirm the metabolic effects of Citrus sudachi peel. 
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